Karen Acevedo Mogharbel, DO
Family Medicine · Mesa, AZNPI 1245222074
Payments from drug & device makers
Across 491 payments — averaging $121.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$41K
- Abbott$12K
- AstraZeneca$2K
- AbbVie$741
- Lilly USA, LLC$732
- Boehringer Ingelheim$697
- plus $3K from 35 others
What the payments were for
- Consulting fees$6,81811%
- Speaking & faculty fees$38,74465%
- Travel & lodging$3,1115%
- Food & beverage$10,56318%
- Education$2230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$22,936
- Ozempic$13,092
- FREESTYLE LIBRE 3$10,938
- Victoza$1,823
- AIMOVIG$244
- AIRSUPRA$228
- FASENRA$126
- FreeStyle Libre 2$125
- Tresiba$125
- UBRELVY$125
- BREZTRI AEROSPHERE$125
- BREZTRI$125
- FARXIGA$125
- SPIRIVA RESPIMAT$119
- INVOKANA$106
How this compares
$59,459 in reported general payments places this provider in the 95th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 209 | $313,099 |
| JardianceEmpagliflozin | 164 | $196,617 |
| Tresiba Flextouch U-200Insulin Degludec | 79 | $69,784 |
| EliquisApixaban | 50 | $60,467 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $52,435 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $43,629 |
| RybelsusSemaglutide | 36 | $43,417 |
| MyrbetriqMirabegron | 30 | $35,750 |
| LinzessLinaclotide | 20 | $31,861 |
| TrulicityDulaglutide | 13 | $24,297 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $14,952 |
| XareltoRivaroxaban | 15 | $10,957 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,828 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $9,235 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $8,393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $40,917 | $356,516245 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $697 | $203,056176 claims |
| PfizerEliquis | $93 | $60,46750 claims |
| GSKTrelegy Ellipta | $132 | $52,43542 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,858 | $49,34646 claims |
| Astellas Pharma US IncMyrbetriq | $120 | $35,75030 claims |
| AbbVieLinzess, Synthroid | $741 | $35,62168 claims |
| Lilly USA, LLCTrulicity | $732 | $24,29713 claims |
| Johnson & JohnsonXarelto | $258 | $10,95715 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $52 | $2,007330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Mesa
- Terry O'ReillyMesa$35.8M
- Corey AndersonMesa$21.5M
- Gerald ShockeyMesa$12.3M
- Rachel GreatwoodMesa$1.5M
- Donna DesantisMesa$776K
- Yadwinder DhillonMesa$445K
- Benjamin ClarkMesa$441K
- Suzanne BentzMesa$174K
- William ReedyMesa$168K
- Allan SooMesa$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.